The companies will work together for development and commercialization of Novosis rhBMP-2 bone growth materials and other solutions for the U.S. and Canada.
Through this acquisition, CONMED acquires next-generation bioinductive collagen scaffold technology for application in sports medicine soft tissue healing.
The action is intended to support increased efficiency in the outpatient ambulatory surgery center market for doctors who treat degenerative spine disease.